Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.50 |
| ▸ | CA1 | P00915 | 11/20 | 0.50 |
| ▸ | CA9 | Q16790 | 9/20 | 0.50 |
| ▸ | CA12 | O43570 | 5/20 | 0.50 |
| ▸ | CA6 | P23280 | 4/20 | 0.50 |
| ▸ | CA5A | P35218 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490894 | 1.00 | CA2 (0.50) | CA2CA1CA9CA12CA6 | |
| SCHEMBL2066500 | 0.82 | CDK2 (0.44) | CA2CA1CA9CA12CA6 | |
| SCHEMBL48859 | 0.80 | ENPP2 (0.43) | — | |
| SCHEMBL8377616 | 0.80 | TSHR (0.46) | CA6CA5ACA4CA7CA5B | |
| SCHEMBL2557830 | 0.79 | CDK2 (0.42) | CA2CA1CA9CA12CA6 | |
| SCHEMBL3448715 | 0.77 | CDK2 (0.41) | CA2CA1CA9CA12CA6 | |
| SCHEMBL289765 | 0.77 | PSIP1 (0.45) | CA9CA12CYP2C9 | |
| SCHEMBL29670227 | 0.77 | PSIP1 (0.45) | CA9CA12CYP2C9 | |
| SCHEMBL202947 | 0.75 | CA2 (0.70) | CA2CA1CA9CA12CA6 | |
| SCHEMBL1742559 | 0.75 | ALDH1A1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-06-09 | — | — | US | disclosed |
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285156-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | CA2 3488/4885CA1 3813/4885CA9 3967/4885 |
| US-12083121-B2 | Substituted piperazines as KRAS G12C inhibitors | KRAS, NRAS, HRAS | CA2 3488/4885CA1 3813/4885CA9 3967/4885 |
| US-20220175782-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA2 2699/4885CA1 2768/4885CA9 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.